(Q38094968)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23546520%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23546520%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

James N Kochenderfer

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23546520%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Steven A Rosenberg

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23546520%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

2 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23546520%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23546520%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23546520%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23546520%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

267-276

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23546520%20AND%20SRC:MED&resulttype=core&format=json

A decade of progress in lymphoma: advances and continuing challenges

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Novel agents for diffuse large B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Management of relapsed diffuse large B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Update on therapy of chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Treatment strategies in advanced stage follicular lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Stem cell transplantation for indolent lymphoma: a reappraisal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Allogeneic transplantation for lymphoma: long-term outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Adoptive immunotherapy for cancer: harnessing the T cell response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Adoptive T cell therapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Treating cancer with genetically engineered T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Cancer regression in patients after transfer of genetically engineered lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Supernatural T cells: genetic modification of T cells for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Genetic modification of human T lymphocytes for the treatment of hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Engineered T cells for anti-cancer therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

The promise and potential pitfalls of chimeric antigen receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

T-cell therapy in the treatment of post-transplant lymphoproliferative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Biologic drugs in autoinflammatory syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Inducible apoptosis as a safety switch for adoptive cell therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.46

B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23546520

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23546520

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23546520

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2013.46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23546520%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23546520%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference